Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 9525 pages

Showing 101 - 150


issues in oncology

IMPACT Study, Aimed at Increasing Diversity Among Clinical Trial Participants, Launches

The University of Southern California (USC) Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities....

health-care policy
cost of care

AMA Commends Final CMS Rule for Requiring Pricing Information in TV Drug Ads

Today, Health and Human Services Secretary Alex Azar announced a final rule from the Centers for Medicare & Medicaid Services (CMS) that will require direct-to-consumer television advertisements for prescription pharmaceuticals covered by Medicare or Medicaid to include the list price—the ...

issues in oncology

WINTHER Trial: Genomic and Transcriptomic Profiling May Translate to New Therapeutic Options for Patients With Advanced Cancer

Published by Rodon et al in Nature Medicine, results of the WINTHER study showed that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial aimed to...

breast cancer

ASBrS 2019: Comprehensive Postoperative Mastectomy Home Recovery Programs Show Patient Benefit

Comprehensive postoperative mastectomy home recovery programs significantly increased same-day patient discharge with no decrease in quality of care, according to two new studies presented at the Annual Meeting of the American Society of Breast Surgeons (ASBrS). “Research demonstrates the...

bladder cancer

AUA 2019: Studies Highlight Potential Bladder Cancer Risks

Electronic cigarettes (e-cigarettes), exposure to certain environmental factors, and human papillomavirus (HPV) infection may increase the risk of developing bladder cancer, according to new data presented this week at the 2019 Annual Meeting of the American Urological Association (AUA). The...

breast cancer
pain management

ASBrS 2019: Opioid Management Program Reduces Post–Breast Surgery Narcotic Use

A breast surgery opioid prescription management program that analyzed current physician patterns and provided education and guidelines successfully reduced the volume of narcotics given postoperatively to patients at a large institution. These results were presented by Fan et al at the Annual...

breast cancer

ASBrS 2019: Retrospective Study of Nipple-Sparing Mastectomy Outcomes Over Time

Nipple-sparing mastectomy complication and implant failure rates have decreased significantly since introduction of the procedure, while the patient population undergoing nipple-sparing mastectomy increasingly includes more advanced cancers and women traditionally considered at risk for...

bladder cancer

AUA 2019: OLYMPUS Trial Assesses Mitomycin Gel in Low-Grade Upper Tract Urothelial Carcinoma

Findings from a secondary analysis of the phase III OLYMPUS trial were presented by Kleinmann et al during the Plenary Session at the 2019 American Urological Association (AUA) Annual Meeting (Abstract LBA-16). Results showed that instillation of UGN-101, an investigational formulation of mitomycin ...

prostate cancer

AUA 2019: Insights in Prostate Cancer Identification and Management

Prostate cancer diagnosis and treatment are ever-changing, with new research showcasing different ways to identify and manage patients with the disease. Three new abstracts—highlighting how beta-blockers may impact prostate cancer risk, the advantages and disadvantages of using magnetic...

breast cancer
symptom management

ASBrS 2019: Bioimpedance Spectroscopy for Surveillance of Breast Cancer–Related Lymphedema

Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy. These were the results of an...

breast cancer

ASBrS 2019: Factors Associated With Nonoperative Management of Select Patients With HER2-Positive Breast Cancer

Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively....

breast cancer

FDA Approves Ado-Trastuzumab Emtansine for HER2-Positive Early Breast Cancer

On May 3, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane- and trastuzumab-based treatment. Patients should be...

breast cancer
prostate cancer
symptom management

ESTRO 38: REQUITE Project Finds Predictive Biomarkers for Late Radiotherapy Toxicity

The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse effects after radiotherapy, have shown that a combination of biologic markers and certain genetic changes can predict radiation sensitivity. In addition, the international team ...

cns cancers

ESTRO 38: What Type of Radiotherapy May Best Preserve Cognitive Function in Pediatric Patients With Brain Tumors?

A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam scanning (PBS) offers the best hope of preserving cognitive functions. The study, presented by Toussaint et al at ESTRO 38, the annual congress of the European Society...

prostate cancer

ESTRO 38: High–Dose Rate Brachytherapy in Localized Prostate Cancer

A single high dose of radiation that can be delivered directly to a treatment site within a few minutes is a safe and effective technique for treating men with localized, low-risk prostate cancer, according to a study presented by Tharmalingam et al at ESTRO 38, the annual congress of the ...

solid tumors
leukemia
prostate cancer
pain management

FDA Pipeline: Applications and Designations in Prostate Cancer, Leukemia, and HER2-Positive Cancers

In the past 2 weeks, the U.S. Food and Drug Administration (FDA) accepted a new drug application and granted Priority Review for a prostate cancer treatment, granted Orphan Drug designation to a treatment for acute lymphoblastic leukemia, accepted an investigational new drug application for a...

leukemia

FDA Approves First-Line Ivosidenib for IDH1-Mutated AML

On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...

lung cancer

ESTRO 38: Radical Hemithoracic Therapy in Patients With Mesothelioma

Patients with mesothelioma are twice as likely to survive for 2 years or longer if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented by Minatel et al at ESTRO 38, the annual congress of the European Society for Radiotherapy...

lymphoma

ESTRO 38: Radiotherapy After ABVD May Improve Survival in Advanced Hodgkin Lymphoma

Patients with advanced Hodgkin lymphoma with bulky lesions at the time of diagnosis may benefit from radiotherapy after chemotherapy, according to late-breaking results presented by Ricardi et al at ESTRO 38, the annual congress of the European Society for Radiotherapy & Oncology...

breast cancer

ESTRO 38: Long-Term Results of Adjuvant Radiotherapy Plus Antihormonal Treatment in Hormone Receptor–Positive Breast Cancer

Women with early-stage, low-risk, hormone receptor–positive breast cancer may be less likely to experience disease recurrence if they have radiotherapy after surgery as well as antihormonal treatment, according to results from a trial that has followed 869 women for 10 years. These findings...

breast cancer

ESMO Breast Cancer 2019: Does Continuous Chemotherapy Benefit Patients With Advanced Breast Cancer?

Continuous chemotherapy showed greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented by Erdkamp et al and Claessens et al at the European...

solid tumors
kidney cancer

Hope and Fear Are Two Constants in the Lives of Patients With Cancer

A year and a half ago, when I was 33, the thought of having a life-threatening disease was unimaginable. In hindsight, the weight loss I began experiencing in the fall of 2017 should have raised concern because I’ve always had to be mindful of my diet if I wanted to lose weight. But denial can be a ...

breast cancer

ESMO Breast Cancer 2019: PERNETTA Trial Examines Treatment De-escalation in Women With HER2-Positive Breast Cancer

De-escalation approaches in the treatment of women with HER2-positive breast cancer need to be personalized, according to a European Society for Medical Oncology (ESMO) spokesperson Carmen Criscitiello, MD, PhD, of the European Institute of Oncology in Milan, Italy. Dr. Criscitello commented on the ...

Hematologist Francesco Lo Coco, MD, Dies in Rome at 63

Hematologist Francesco Lo Coco, MD, known for his research accomplishments in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL), died in Rome on March 3, 2019. He was 63. After graduating from the Medical School in Pisa, he moved to La Sapienza University of Rome in 1981....

Robert O. Hickman, MD, Inventor of the Hickman Catheter, Dies at 92

Robert O. Hickman, MD, a pediatric nephrologist and inventor of a catheter that revolutionized care for patients with cancer, died on April 4, 2019. He was 92. Dr. Hickman was born on September 27, 1926, in Monticello, Utah. He served in the U.S. Air Force in the mid-1940s and married Lucy Jean...

Nobel Laureate and Pioneer in Molecular Biology, Sydney Brenner, MSc, MBBCh, DPhil, Dies at 92

Sydney Brenner, MSc, MBBCh, DPhil, died on April 6, 2019, at age 92, according to The Agency for Science, Technology and Research (A*STAR) in Singapore, where Dr. Brenner had served as a Senior Fellow. Dr. Brenner was conferred the Nobel Prize in Physiology or Medicine in 2002 for his pioneering...

The Skin Cancer Foundation Awards $125,000 in Research Grants

The Skin Cancer Foundation hosted its member reception on March 1 during the American Academy of Dermatology (AAD) Annual Meeting. As part of the reception, the Foundation announced the winners of its annual research grant awards, collectively totaling $125,000. David Polsky, MD, Chair of The Skin...

Cigall Kadoch, PhD, Chosen for 2019 Martin and Rose Wachtel Cancer Research Prize

The American Association for the Advancement of Science and Science Translational Medicine announced that Cigall Kadoch, PhD, has been chosen for the 2019 Martin and Rose Wachtel Cancer Research Prize. Dr. Kadoch is Assistant Professor of Pediatric Oncology at Dana-Farber Cancer Institute;...

issues in oncology

How Hepatitis C Virus Screening May Improve Survival in Patients With Cancer

In 2013, the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommended that all people born between 1945 and 1965 undergo one-time screening for the hepatitis C virus (HCV), because the rates of HCV infection are markedly higher for baby...

Ali McBride, PharmD, MS, BCOP, Named 2019–2020 ACCC President

Ali McBride, PharmD, MS, BCOP, was named 2019–2020 President of the Association of Community Cancer Centers (ACCC) during its 45th Annual Meeting & Cancer Center Business Summit on March 22, 2019. Dr. McBride is the Clinical Coordinator of Hematology/Oncology at The University of Arizona...

issues in oncology

FDA Oncology Center of Excellence Issues Annual Report

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report,1 including updates on regulatory reviews and initiatives, OCE programs, guidances, and more. The OCE is tasked with clinical medical oncology reviews, irrespective of whether the...

solid tumors
bladder cancer

FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma

On April 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing...

hematologic malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

GUEST EDITORS Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...

Expert Point of View: Charles B. Simone II, MD

In a press briefing that preceded the 2019 Multidisciplinary Thoracic Cancers Symposium, Charles B. Simone II, MD, a radiation oncologist and Chief Medical Officer at the New York Proton Center, noted that this study should help clinicians better understand the impact of local therapy for patients ...

breast cancer

ESMO Breast Cancer 2019: Outcomes in Younger Patients With Breast Cancer

Breast cancer in young women is characterized by more aggressive biologic features as compared to older patients, but outcomes are good when guideline-recommended treatments are given. European Society for Medical Oncology (ESMO) spokesperson Matteo Lambertini, MD, PhD, of IRCCS Policlinico San...

Mark E. Thompson, MD, Named Medical Director for Public Policy at Community Oncology Alliance

The Community Oncology Alliance (COA) recently announced that Mark E. Thompson, MD, has been appointed to the newly created staff position of Medical Director for Public Policy. Dr. Thompson will chair the COA Government Affairs and Policy Committee, a standing committee that guides official...

breast cancer

ESMO Breast Cancer 2019: Evidence-Based Educational Nutrition Intervention Among Patients With Early-Stage Breast Cancer

Although tools like the ESPEN guidelines on nutrition for patients with cancer have helped to standardize practices in this area of patient care, scientific evidence on the efficacy of nutritional intervention among patients with breast cancer is still scarce. Preliminary results from a study to be ...

breast cancer
issues in oncology
global cancer care

ESMO Breast Cancer 2019: ONCOLLEGE-001: Global Survey of HER2 Testing

A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2-targeted therapies for breast cancer, especially in lower-income countries. These results will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer...

OneOncology Announces Lee Schwartzberg, MD, FACP, as Chief Medical Officer

OneOncology, the national partnership of community oncologists, has announced that Lee Schwartzberg, MD, FACP, has been named Chief Medical Officer. The Chief Medical Officer position provides a link between OneOncology and its physician partners, demonstrating the shared, foundational commitment...

colorectal cancer

Colon Cancer Proteogenomic Analysis May Uncover New Potential Treatments

A new study analyzing the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor, pointing to novel cancer biologic mechanisms and possible new therapeutic strategies. This multidisciplinary and...

symptom management

New Biomarkers Associated With Cancer-Related Cognitive Impairment Identified

Cognitive impairment associated with cancer—also known as “chemobrain”—has gained recognition as a complication of the disease and its treatment. With this in mind, a research team started to investigate levels of biomarkers in relation to chemobrain to better understand its ...

Joe Biden and Dr. Jill Biden Step Down From Biden Cancer Initiative Board

In light of the launch of his campaign for the 2020 Democratic presidential nomination, former Vice President Joe Biden and Dr. Jill Biden announced that they are stepping down as Co-Chairs of the Biden Cancer Initiative. They are also resigning from the Board of Directors. “[W]e are glad...

sarcoma

Access Program to Be Established for Patients After Olaratumab Is Withdrawn From the Global Market

On April 25, Eli Lilly and Company announced that the company has been working to facilitate the withdrawal of olaratumab from the market for the treatment of advanced soft-tissue sarcoma. Lilly's actions to withdraw olaratumab from the market follow completion of the international phase III...

health-care policy
hematologic malignancies
immunotherapy

ASH President Comments on Medicare Proposal for CAR T-Cell Therapy

Earlier this week, the Centers for Medicare & Medicaid Services (CMS) proposed to improve the reimbursement currently given to hospitals that provide chimeric antigen receptor T-cell (CAR-T) therapy to patients with blood cancer as part of the Fiscal Year 2020 Inpatient Prospective Payment...

hepatobiliary cancer

Ramucirumab After Sorafenib in Advanced Hepatocellular Carcinoma: An Efficacious Therapy With Applicability Challenges

In the 2 years since the U.S. Food and Drug Administration’s (FDA) approval of regorafenib in the treatment of patients with sorafenib-refractory advanced hepatocellular carcinoma, we oncologists have witnessed a veritable avalanche of newly approved medicines for the treatment of advanced...

Giulio Draetta, MD, PhD, Named Chief Scientific Officer at MD Anderson

The University of Texas MD Anderson Cancer Center has named Giulio Draetta, MD, PhD, as Chief Scientific Officer, a new position that champions innovation, develops strong partnerships, and provides focused leadership on the science and clinical translation of research programs. Dr. Draetta joined ...

solid tumors

NCCN Awards Grants to Study Trifluridine and Tipiracil

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program has funded three investigators from NCCN Member Institutions—Patrick Boland, MD, and Sarbajit Mukherjee, MD, MS, both of Roswell Park Comprehensive Cancer Center; and Amit Mahipal, MBBS, of Mayo Clinic Cancer Center—to...

Expert Point of View: Rafael Fonseca, MD

Rafael Fonseca, MD, the Getz Family Professor of Cancer and Chair of the Department of Medicine, Mayo Clinic in Arizona and an expert in minimal residual disease (MRD) in myeloma, commented on the PRIMeR study for The ASCO Post. The PRIMeR subanalysis of the STaMINA trial showed the prognostic...

Ryan C. Fields, MD, Named Chief of Surgical Oncology at Washington University in St. Louis

Ryan C. Fields, MD, has been named Chief of the Section of Surgical Oncology at Washington University School of Medicine in St. Louis. Dr. Fields, who joined the faculty in 2011, is also Associate Professor of Surgery, Associate Program Director of the General Surgery Residency Program, and...

Antoni Ribas, MD, PhD, Elected AACR President-Elect 2019–2020

The members of the American Association for Cancer Research (AACR) recently elected Antoni Ribas, MD, PhD, as its President-Elect for 2019–2020. He officially became President-Elect at the 2019 AACR Annual Meeting and will assume the presidency at the 2020 AACR Annual Meeting in San Diego. The...

Advertisement

Advertisement



;
Advertisement